**Background of SART3 Antibody**
SART3 (Squamous Cell Carcinoma Antigen Recognized by T Cells 3), also known as **hnRNP G-T** or **p110**, is a tumor-associated antigen predominantly expressed in the nuclei of cancer cells. It plays dual roles in cellular processes: as a component of the mRNA splicing machinery via its association with the U4/U6.U5 tri-snRNP complex, and as a target for cytotoxic T lymphocytes (CTLs) in cancer immunotherapy.
SART3 is overexpressed in various malignancies, including squamous cell carcinomas, melanoma, and leukemia, making it a potential biomarker and therapeutic target. Its antigenic peptide, presented by HLA class I molecules, triggers CTL-mediated immune responses, driving interest in SART3-based cancer vaccines or adoptive T-cell therapies.
Antibodies targeting SART3 are essential tools for studying its expression, localization, and function in cancer biology. They enable detection of SART3 in tumor tissues, investigation of its role in RNA splicing, and evaluation of its immunogenic properties. Research using SART3 antibodies has also explored its paradoxical roles—while promoting tumorigenesis in some contexts, it may act as a tumor suppressor in others, depending on cellular context and interaction partners.
Overall, SART3 antibodies contribute to advancing cancer diagnostics, understanding tumor-immune interactions, and developing targeted immunotherapies.